Medline ® Abstract for Reference 117
of 'Complementary and alternative therapies for cancer'
Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI
Prostate Cancer Prostatic Dis. 2003;6(4):301.
This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value<0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.
Prostate Oncology Specialist, Marina del Rey, California 90292, USA. Brad@prost8cancer.com